• 1
    The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators: A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997; 337: 15761578.
  • 2
    Gold MR, Nisam S: Multicenter Automatic Defibrillator Implantation Trial, Multicenter Unsustained Tachycardia Trial. Primary prevention of sudden cardiac death with implantable cardioverter defibrillators: Lessons learned from MADIT and MUSTT. Pacing Clin Electrophysiol 2000; 23: 19811985.
  • 3
    Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, et al.: Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346: 877883.
  • 4
    Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, et al.: Plasma natriuretic peptide levels and risk of cardiovascular events and death. N Engl J Med 2004; 350: 655663.
  • 5
    Berger R, Huelsman M, Strecker K, Bojic A, Moser P, et al.: B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002; 105: 23922395.
  • 6
    Tapanainen JT, Lindgren KS, Makikallio TH, Vulteenaho O, Leppaluoto J, et al.: Natriuretic peptides as predictors of non-sudden and sudden cardiac death after acute myocardial infarction in the beta blocking era. J Am Coll Cardiol 2004; 43: 757763.
  • 7
    Manios EG, Kallergis EM, Kanoupakis EM, Mavrakis HE, Kambouraki DC, et al.: Amino-terminal pro-brian natriuretic peptide predicts ventricular arrhythmogenesis in patients with ischemic cardiomyopathy and implantable cardioverter-defibrillators. Chest 2005; 128: 26042610.
  • 8
    Verma A, Kilicaslan F, Martin DO, Minor S, Starling R, et al.: Preimplantation B-type natriuretic peptide concentration is an independent predictor of future appropriate implantable defibrillator therapies. Heart 2006; 92: 190195.
  • 9
    Blangy H, Sadoul N, Dousset B, Radauceanu A, Fay R, et al.: Serum BNP, hs-C-reactive protein, procollagen to assess the risk of ventricular tachycardia in ICD recipients after myocardial infarction. Europace (Epub ahead of print; May 24, 2007).
  • 10
    Whang W, Mittleman MA, Rich DQ, Wang PJ, Ruskin JN, et al., TOVA Investigators: Heart failure and the risk of shocks in patients with implantable cardioverter defibrillators: Results from the triggers of ventricular arrhythmias (TOVA) study. Circulation 2004; 109: 13861391.
  • 11
    Kohl P, Bollensdorff C, Garny A: Effects of mechanosensitive ion channels on ventricular electrophysiology: Experimental and theoretical models. Exp Physiol 2006; 91: 307321.
  • 12
    Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med 2005;353: 14711480.